Skip to main content

Analysts’ Top Healthcare Picks: Hinge Health, Inc. Class A (HNGE), Scholar Rock Holding (SRRK)

Tipranks - Tue Dec 2, 2025

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Hinge Health, Inc. Class A (HNGEResearch Report), Scholar Rock Holding (SRRKResearch Report) and Galecto (GLTOResearch Report) with bullish sentiments.

TipRanks Cyber Monday Sale

Hinge Health, Inc. Class A (HNGE)

Truist Financial analyst Jailendra Singh maintained a Buy rating on Hinge Health, Inc. Class A today. The company’s shares closed last Friday at $48.91.

According to TipRanks.com, Singh has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -15.4% and a 32.4% success rate. Singh covers the Healthcare sector, focusing on stocks such as Fortrea Holdings Inc., Privia Health Group, and Hims & Hers Health. ;'>

Currently, the analyst consensus on Hinge Health, Inc. Class A is a Strong Buy with an average price target of $66.48.

See the top stocks recommended by analysts >>

Scholar Rock Holding (SRRK)

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Scholar Rock Holding. The company’s shares closed last Friday at $44.06, close to its 52-week high of $46.98.

According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of 13.9% and a 55.0% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Madrigal Pharmaceuticals, and MBX Biosciences, Inc. ;'>

Currently, the analyst consensus on Scholar Rock Holding is a Strong Buy with an average price target of $46.78, implying an 8.1% upside from current levels. In a report issued on November 18, J.P. Morgan also maintained a Buy rating on the stock with a $47.00 price target.

Galecto (GLTO)

In a report released yesterday, Bradley Canino from Guggenheim initiated coverage with a Buy rating on Galecto and a price target of $32.00. The company’s shares closed last Friday at $17.78, close to its 52-week high of $20.50.

According to TipRanks.com, Canino is a 4-star analyst with an average return of 11.9% and a 44.2% success rate. Canino covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Syndax Pharmaceuticals, and Janux Therapeutics Inc. ;'>

Currently, the analyst consensus on Galecto is a Moderate Buy with an average price target of $32.00.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.